Soluble urokinase receptor and chronic kidney disease

New England Journal of Medicine

Volumn 373, Issue 20, 2015, Pages 1916-1925

  Hayek, Salim S ^a   Sever, Sanja ^c,d   Ko, Yi An ^a,b   Trachtman, Howard ^e   Awad, Mosaab ^a   Wadhwani, Shikha ^f   Altintas, Mehmet M ^f   Wei, Changli ^f   Hotton, Anna L ^g   French, Audrey L ^f,g   Sperling, Laurence S ^a   Lerakis, Stamatios ^a   Quyyumi, Arshed A ^a   Reiser, Jochen ^f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g Women's Interagency HIV Study   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; BLOOD; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; STATISTICAL MODEL;

AGED; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84946888250     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506362     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-52.
3. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
4. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-26.
5. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-77.
6. Thun. M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-72.
7. Wei C, M.ller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
8. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-9.
9. De Witte H, Sweep F, Brunner N, et al. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998; 77: 236-42.
10. Sier CF, Sidenius N, Mariani A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999; 79: 717-22.
11. Gustafsson A, Ajeti V, Ljunggren L. Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomark Insights 2011; 6: 119-25.
12. Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med 2015; 277: 362-71.
13. Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol 2015; 26: 133-47.
14. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39.
15. Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012; 38: 1418-28.
16. Borné Y, Persson M, Melander O, Smith JG, Engstr.m G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014; 16: 377-83.
17. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
18. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis 2012; 222: 8-14.
19. Lyngb.k S, Marott JL, Sehestedt T, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 2013; 167: 2904-11.
20. Eapen DJ, Manocha P, Ghasemzedah N, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 2014; 3(5): e001118.
21. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-60.
22. Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23: 2051-9.
23. Spinale JM, Mariani LH, Kapoor S, et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 2015; 87: 564-74.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: Suppl 1: S1-S266.
25. Jeppesen J, Hansen TW, Olsen MH, et al. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil 2008; 15: 594-8.
26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
27. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011; 30: 1105-17.
28. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9: 117-25.
29. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol 2001; 154: 563-73.
30. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-65.
31. Maile LA, Gollahon K, Wai C, Dunbar P, Busby W, Clemmons D. Blocking alphaVbeta3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats. J Diabetes Res 2014: 421827.
32. Maile LA, Busby WH, Gollahon KA, et al. Blocking ligand occupancy of the V3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology 2014; 155: 4665-75.
33. Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 2014; 6: 256ra136.
34. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 2008; 80: 209-16.
35. Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J 2004; 34: 50-7.
36. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-21.
37. Meijers B, Poesen R, Claes K, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int 2015; 87: 210-6.
38. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-50.